108 related articles for article (PubMed ID: 27174460)
1. The renin-angiotensin system in Barrett's esophagus.
Bratlie SO; Edebo A; Casselbrant A; Helander HF; Fändriks L
Scand J Gastroenterol; 2016 Sep; 51(9):1037-42. PubMed ID: 27174460
[TBL] [Abstract][Full Text] [Related]
2. Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus.
Bratlie SO; Casselbrant A; Edebo A; Fändriks L
Scand J Gastroenterol; 2017 Mar; 52(3):338-343. PubMed ID: 27846743
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
4. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
5. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
6. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
7. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
8. ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett's esophagus.
Nishigaki H; Wada K; Tatsuguchi A; Sueoka N; Futagami S; Gudis K; Miyake K; Tsukui T; Sakamoto C
Digestion; 2004; 70(2):95-102. PubMed ID: 15375338
[TBL] [Abstract][Full Text] [Related]
9. Presence or absence of intestinal metaplasia but not its burden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus.
Bansal A; McGregor DH; Anand O; Singh M; Rao D; Cherian R; Wani SB; Rastogi A; Singh V; House J; Jones PG; Sharma P
Dis Esophagus; 2014; 27(8):751-6. PubMed ID: 24165297
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
11. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
12. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
13. Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma.
Upton MP; Nishioka NS; Ransil BJ; Rosenberg SJ; Puricelli WP; Zwas FR; Shields HM
Dig Dis Sci; 2006 Oct; 51(10):1783-90. PubMed ID: 16967312
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
17. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
18. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Schmidt MK; Meurer L; Volkweis BS; Edelweiss MI; Schirmer CC; Kruel CD; Gurski RR
Dis Esophagus; 2007; 20(3):212-6. PubMed ID: 17509117
[TBL] [Abstract][Full Text] [Related]
19. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
